Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
Status:
Terminated
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of perhexiline on exercise performance
(efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe
heart failure following dosing for 16 weeks.